227 related articles for article (PubMed ID: 35208498)
1. Combined Positive Score for Programmed Death Ligand-1 Expression and Inflammatory Microenvironment in Gastrointestinal Stromal Tumors.
Herlea V; Roșulescu A; Calotă VC; Croitoru V; Stoica Mustafa E; Vasilescu C; Alexandrescu S; Dumitrașcu T; Popescu I; Dima SO; Sajin M
Medicina (Kaunas); 2022 Jan; 58(2):. PubMed ID: 35208498
[No Abstract] [Full Text] [Related]
2. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
3. Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors.
Sun X; Sun J; Yuan W; Gao X; Fu M; Xue A; Li H; Shu P; Fang Y; Hou Y; Shen K; Sun Y; Qin J; Qin X
J Gastrointest Surg; 2021 Aug; 25(8):2091-2100. PubMed ID: 33169322
[TBL] [Abstract][Full Text] [Related]
4. Role of immune microenvironment in gastrointestinal stromal tumours.
Blakely AM; Matoso A; Patil PA; Taliano R; Machan JT; Miner TJ; Lombardo KA; Resnick MB; Wang LJ
Histopathology; 2018 Feb; 72(3):405-413. PubMed ID: 28871595
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
Nam SJ; Kim YH; Park JE; Ra YS; Khang SK; Cho YH; Kim JH; Sung CO
Cancer Immunol Immunother; 2019 Feb; 68(2):305-318. PubMed ID: 30483834
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
7. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer.
Kim JW; Nam KH; Ahn SH; Park DJ; Kim HH; Kim SH; Chang H; Lee JO; Kim YJ; Lee HS; Kim JH; Bang SM; Lee JS; Lee KW
Gastric Cancer; 2016 Jan; 19(1):42-52. PubMed ID: 25424150
[TBL] [Abstract][Full Text] [Related]
10. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
[TBL] [Abstract][Full Text] [Related]
11. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
[TBL] [Abstract][Full Text] [Related]
12. Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases.
Dislich B; Stein A; Seiler CA; Kröll D; Berezowska S; Zlobec I; Galvan J; Slotta-Huspenina J; Walch A; Langer R
Cancer Immunol Immunother; 2017 Jun; 66(6):777-786. PubMed ID: 28289861
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes.
Rivera-Colon G; Chen H; Molberg K; Niu S; Strickland AL; Castrillon DH; Carrick K; Gwin K; Lea J; Zheng W; Lucas E
Am J Surg Pathol; 2021 Jun; 45(6):742-752. PubMed ID: 33298732
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma.
Ottenhof SR; Djajadiningrat RS; Thygesen HH; Jakobs PJ; Jóźwiak K; Heeren AM; de Jong J; Sanders J; Horenblas S; Jordanova ES
Front Immunol; 2018; 9():1253. PubMed ID: 29942303
[TBL] [Abstract][Full Text] [Related]
17. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
18. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
19. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L
BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
